TMCnet News
NeonMind to Webcast Live at Life Sciences Investor Forum on June 24thVANCOUVER, British Columbia, June 22, 2021 (GLOBE NEWSWIRE) -- NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that Robert Tessarolo, President and Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on June 24th. DATE: Thursday, June 24th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.lifesciencesinvestorforum.com. Recent Company Highlights
About NeonMind Biosciences Inc. In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5-HT2A, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite. NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. NeonMind’s consumer division currently sells NeonMind-branded coffee products in Canada through NeonMind’s direct to consumer e-commerce platform, and it has plans to launch dietary supplements in the United States this quarter. For more information on NeonMind, go to www.NeonMindBiosciences.com. About Life Sciences Investor Forum A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network. The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release. Cautionary Statement Regarding Forward-Looking Statements CONTACTS: Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc. [email protected] Tel: 416-750-3101 Investor Relations: Edge Communications [email protected] Tel: 1-866-318-6874 KCSA Strategic Communications Scott Eckstein/Tim Regan [email protected] Tel: 212-896-1210 Renmark Financial Communications Inc. Melanie Barbeau [email protected] Tel: 416-644-2020 or 212-812-7680 Media Inquiries: KCSA Strategic Communications Annie Graf [email protected] Tel: 786-390-2644 Exvera Communications Inc. [email protected] Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 [email protected] |